Market Place
Sourcing Support
Biomea Fusion Reports Inducement Grant under Nasdaq LR 5635(c)(4)
01 Nov 2024 //
GLOBENEWSWIRE
Biomea Preclinical Data Icovamenib Enhance Effectiveness of GLP-1
30 Oct 2024 //
GLOBENEWSWIRE
Biomea Fusion Reports Q3 2024 Financial Results and Highlights
29 Oct 2024 //
GLOBENEWSWIRE
Biomea Fusion Announces Approval Of “icovamenib” For BMF-219
21 Oct 2024 //
GLOBENEWSWIRE
Biomea Fusion to Host Conference Call and Webcast on Oct 30th
15 Oct 2024 //
GLOBENEWSWIRE
Biomea Fusion To Present At1st ATTD-ASIA 2024 Conference
07 Oct 2024 //
GLOBENEWSWIRE
Biomea Forms Global Scientific Advisory Board for Diabetes
01 Oct 2024 //
GLOBENEWSWIRE
FDA lifts clinical hold on Biomea`s diabetes trials
27 Sep 2024 //
REUTERS
FDA Lifts Clinical Hold On BMF-219 In Diabetes Trials
26 Sep 2024 //
GLOBENEWSWIRE
Biomea Fusion Reports Inducement Grant Under Nasdaq Rule
01 Aug 2024 //
GLOBENEWSWIRE
Biomea Fusion Reports Q2 2024 Financial Results And Highlights
31 Jul 2024 //
GLOBENEWSWIRE
Diabetes biotech stock tanks as FDA imposes full clinical hold
07 Jun 2024 //
FIERCE BIOTECH
U.S. FDA places clinical hold on Biomea`s diabetes trials
07 Jun 2024 //
PRESS RELEASE
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
06 Jun 2024 //
GLOBENEWSWIRE
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule
03 Jun 2024 //
GLOBENEWSWIRE
Biomea Fusion Completes Enrollment 3 Arms BMF-219 Type 2 Diabetes Trial
30 May 2024 //
GLOBENEWSWIRE
Biomea Fusion Q1 2024 Results, Highlights
02 May 2024 //
GLOBENEWSWIRE
Biomea Fusion: Inducement Grants Under Nasdaq Rule 5635(c)(4)
01 May 2024 //
GLOBENEWSWIRE
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
Biomea Highlights Initial Data from the Type 1 Diabetes Dosed with BMF-219
01 Apr 2024 //
GLOBENEWSWIRE
Biomea Fusion Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2024 //
GLOBENEWSWIRE
Biomea Fusion Presents Patient Cohorts in COVALENT-111
06 Mar 2024 //
GLOBENEWSWIRE
Biomea Fusion Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
GLOBENEWSWIRE
Biomea Fusion Highlights Updates and Anticipated 2024 Corporate Milestones
09 Jan 2024 //
GLOBENEWSWIRE
Biomea Announces Dosing of First Type 1 Diabetes Patient in Ph II with BMF-219
08 Jan 2024 //
GLOBENEWSWIRE
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Biomea Presents Achievement of MRD-neg in Responder from Phase I of BMF-219
11 Dec 2023 //
GLOBENEWSWIRE
Biomea Announces Doubling Percentage of Patients with Durable HbA1c Reduction
09 Dec 2023 //
GLOBENEWSWIRE
Biomea Presents Data Showing Improved Glycemic Control in PII Study of BMF-219
08 Dec 2023 //
GLOBENEWSWIRE
Biomea Announces Health Canada Clearance of CTA for BMF-219 in Type 1 Diabetes
05 Dec 2023 //
GLOBENEWSWIRE
Biomea Announces Acceptance of Abstracts for Menin Highlighting Glycemic Control
27 Nov 2023 //
GLOBENEWSWIRE
Biomea Fusion Abstract BMF-219: A Novel Therapeutic Agent
16 Nov 2023 //
GLOBENEWSWIRE
Biomea Fusion to Present New Data from Ongoing Phase II of BMF-219
08 Nov 2023 //
GLOBENEWSWIRE
Biomea Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
02 Nov 2023 //
GLOBENEWSWIRE
Biomea Fusion Reports Third Quarter 2023 Financial Results
30 Oct 2023 //
GLOBENEWSWIRE
Biomea Fusion Announces First Patient Dosed with BMF-500
17 Oct 2023 //
GLOBENEWSWIRE
Biomea Fusion Announces FDA Clearance of IND Application for BMF-219
05 Oct 2023 //
GLOBENEWSWIRE
Biomea Announces FDA and Health Canada Clearance of COVALENT-111 Phase II Study
28 Sep 2023 //
GLOBENEWSWIRE
Biomea Fusion Announces Appointment of Juan Pablo FrÃas, M.D. as CMO
31 Aug 2023 //
GLOBENEWSWIRE
Biomea Fusion Reports Second Quarter 2023 Financial Results
31 Jul 2023 //
GLOBENEWSWIRE
BMF-219 Induces Complete Responses in Target AML Patient Population
24 Jul 2023 //
GLOBENEWSWIRE
Biomea Fusion stock soars after release of clinical data on diabetes treatment
26 Jun 2023 //
MARKETWATCH
Biomea Fusion Presents +VE Data from Initial Cohorts of the Ongoing Ph II Study of BMF-219
23 Jun 2023 //
GLOBENEWSWIRE
Biomea Fusion to Present Late Breaking Data Ongoing PhII Trial, COVALENT-111
21 Jun 2023 //
FINANCIAL EXPRESS
Biomea Fusion to Present Late Breaking Data Ongoing PhII Trial, COVALENT-111
20 Jun 2023 //
GLOBENEWSWIRE
Biomea Fusion patents GTPase KRAS inhibitors
07 Jun 2023 //
BIOWORLD
Biomea Fusion Reports First Quarter 2023 FYR and Corporate Highlights
02 May 2023 //
GLOBENEWSWIRE
Biomea Fusion Announces FDA Clearance of IND for Covalent FLT3 Inhibitor BMF-500
01 May 2023 //
GLOBENEWSWIRE
Biomea Fusion to Present Late Breaking Data Ongoing Ph II Trial, COVALENT-111
19 Apr 2023 //
GLOBENEWSWIRE
Biomea Fusion to Present Data from PII Trial, COVALENT-111, Evaluating BMF-219
19 Apr 2023 //
FINANCE YAHOO
Biomea Fusion Announces Closing of Upsized Public Offering
13 Apr 2023 //
GLOBENEWSWIRE
Biomea Fusion To Present Two Preclinical Posters at 114th AACR Annual Meeting
13 Apr 2023 //
GLOBENEWSWIRE
Biomea Fusion Announces Proposed Public Offering of Common Stock
29 Mar 2023 //
GLOBENEWSWIRE
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock
29 Mar 2023 //
GLOBENEWSWIRE
Biomea Announces Data from Initial Cohorts of Ongoing PII Study of BMF-219
28 Mar 2023 //
GLOBENEWSWIRE
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Biomea Fusion stock soars on early-stage diabetes data
28 Mar 2023 //
ENDPTS
Biomea Fusion to Host Conference Discuss Initial Ph II Data for BMF-219
23 Mar 2023 //
GLOBENEWSWIRE
Biomea Fusion To Participate In Upcoming Investor Events
02 Mar 2023 //
GLOBENEWSWIRE
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial of BMF-219
17 Jan 2023 //
GLOBENEWSWIRE
